Novo Nordisk’s weight loss drug sales to HIMS users exceed 200,000 by Q4 2026

HIMS reached a deal to sell Novo Nordisk’s weight loss drugs, a key growth driver. With obesity treatment demand rising, Novo Nordisk’s GLP-1 drugs could see rapid adoption among HIMS’s subscriber base. Analysts project strong uptake in telehealth weight loss programs.

Implied probability (Yes)

80%